PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study
Stephen R. Daniels, Sonia Caprio, Umesh Chaudhari, Garen Manvelian, Marie T. Baccara-Dinet, Aurélie Brunet, Michel Scemama, Virginie Loizeau, Éric Bruckert
Topics & Concepts
AlirocumabMedicinePCSK9Familial hypercholesterolemiaStatinInternal medicineKexinClinical endpointEvolocumabGastroenterologyEndocrinologyCholesterolApolipoprotein BLipoproteinClinical trialLDL receptorApolipoprotein A1Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCholesterol and Lipid Metabolism